Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS: In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline serum creatinine level. RESULTS: The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P=0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The proportion of patients with hyperkalemia (serum potassium level, ≥6 mmol per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P<0.001 for both comparisons). CONCLUSIONS: The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful. (Funded by Novartis; ALTITUDE ClinicalTrials.gov number, NCT00549757.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ACE inhibitors and ARBs should not be used together and should be used with caution with spironolactone to avoid hyperkalemia or AKI.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [259]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Prior trials of dual renin–angiotensin system blockade have failed to show cardiovascular or kidney protection among patients with CKD and type 2 diabetes”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [25]
In the citing paper
“markedly lower than in trials of dual RAS blockade (4.8% with combination therapy with a direct renin inhibitor and an ACE inhibitor or ARB 20 and 9.2% with dual ACE inhibitor and ARB therapy 22 )”
From Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (2020) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Self-citationTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Self-citation
Research works printed but not linked: 1
- Pfeffer MA, 2010, Dial Cardiovasc Med, 15, 130
Cited by
Items 901–1,000 of 1,000
Du, N., Liu, S., Cui, C., Zhang, M., Jia, J., & Cao, X. (2016) · Renal Failure · doi:10.1080/0886022x.2016.1256319 · Cited by 5
Slowing Progression of Chronic Kidney Disease
Pollack-Zollman, M., & Vassalotti, J. A. (2019) · Oxford University Press eBooks · doi:10.1093/med/9780190611620.003.0012 · Cited by 4
Krairittichai, U., Sarinnapakorn, V., Mahannopkul, R., & Ainwan, P. (2017) · PubMed · Cited by 4
Angelow, A., Ploner, T., Grimmsmann, T., Walker, J., & Chenot, J. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4965 · Cited by 4
“The VA NEPHRON-D study and several large clinical trials and meta-analyses confirmed an increased risk of hyperkalaemia, hypotension, and impaired renal function for a dual RAS blockade with ACEI and ARB or a direct renin inhibitor (aliskiren) with ACEI or ARB compared with monotherapy with RAS blocking agents.(9-14)…”
ResultMedikamentöse antihypertensive Therapie: Wo stehen wir?
Middeke, M. (2015) · Der Internist · doi:10.1007/s00108-014-3570-2 · Cited by 6
Chapter 5. Treatment with antihypertensive drugs
(2014) · Hypertension Research · doi:10.1038/hr.2014.8 · Cited by 6
Aliskiren in Type 2 Diabetes and Cardiorenal End Points
Pfeffer, M. A., Brenner, B. M., & McMurray, J. J. V. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1300257 · Cited by 4
Self-citationClase, C. M., & Mann, J. F. E. (2014) · Annals of Internal Medicine · doi:10.7326/0003-4819-160-6-201403180-02003 · Cited by 4
Novartis Reply to the ATMOSPHERE Data Monitoring Committee
Tougas, G. H., & Aftring, R. P. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1603515 · Cited by 4
Finerenone in diabetic kidney disease – So far, so good
Gilbert, R. E. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.12.012 · Cited by 4
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
Romagnani, P., Soler, M. J., & Fervenza, F. C. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2513088 · Cited by 5
Akbariromani, H., Haseeb, R., Nazly, S., Pandey, S., Chunchu, V. A., Dhakal, S., Avena, M. A. C., & Ali, N. (2022) · Cureus · doi:10.7759/cureus.28608 · Cited by 3
“To date, no published meta-analysis and systematic review have been conducted to evaluate the efficacy of direct renin inhibitors as monotherapy or in combination with ARB and ACEI.”
ResultInfluentialJongs, N., Gasparyan, S. B., Frison, L., Schloemer, P., BRINKER, M. D., Little, D. J., & Heerspink, H. J. L. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000766 · Cited by 3
Pavlos, D., Petsas, E., Chatzipieris, F. P., Mavromoustakos, T., & Chasapis, C. T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311398 · Cited by 3
“The top 20 poses underwent Glide docking and glide redocking with Glide XP to yield IFD scores (GlideScore + 0.05 × Prime energy) [28].”
InfluentialNakamura, M., Satoh, N., Mizuno, T., Takagi, M., Horita, S., & Nangaku, M. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1677518 · Cited by 3
Renin Inhibition and eNOS Upregulation as Novel Mechanisms of Antihypertensive Food Peptides
Ashaolu, T. J. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70163 · Cited by 3
“These limitations highlight the need for safer alternatives, such as food‐derived peptides [22, 23].”
Park, S. J., An, H. S., Kim, S. H., Kim, S. H., Cho, H., Kim, J. H., Cho, A., Kwak, J. H., Shin, J. I., Lee, K. H., et al. (2025) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.24.096 · Cited by 3
Irons, B. K., Trujillo, A., Seifert, C. F., Simoni, J. M., Doctolero, S., Abo‐Salem, E., & Meyerrose, G. E. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413489772 · Cited by 3
“However, one of the previously mentioned studies investigating the potential benefit of adding aliskiren to an ACE-I or ARB in patients with diabetes and renal impairment was terminated prematurely due an increased risk for hypotension and hyperkalemia and a higher incidence of stroke or death, worsening renal functio…”
ResultNovel Blockers of the Renin-Angiotensin-Aldosterone System in Chronic Heart Failure
Valluri, A., Struthers, A. D., & Lang, C. C. (2013) · Current Heart Failure Reports · doi:10.1007/s11897-013-0173-5 · Cited by 3
Renin inhibition in patients with chronic kidney disease: Is it conclusively non-indicated?
Sarafidis, P. A., & Bakris, G. L. (2014) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320313485895 · Cited by 3
“98 Journal of the Renin-Angiotensin-Aldosterone System 15(1)”
Putting Evidence Based JNC 8 Guideline into Primary Care Practice
Ubaidi, B. A. A. (2015) · Journal of Hypertension Open Access · doi:10.4172/2167-1095.1000193 · Cited by 3
“The danger increases with the use of RAAS combined with a direct renin inhibitor such as aliskiren [30,31].”
BackgroundJiménez, D. L., Guerra, L. C., Chozas, J. M. L., & Miramontes‐González, J. P. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.11.022 · Cited by 3
Idzerda, N. M. A., Tye, S. C., de Zeeuw, D., & Heerspink, H. J. L. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820974191 · Cited by 3
Chowdhury, T. A., & Ali, O. (2021) · Clinical Medicine · doi:10.7861/clinmed.2021-0144 · Cited by 3
Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem
Abrignani, M. G., Gronda, E., Marini, M., Gori, M., Iacoviello, M., Temporelli, P. L., Benvenuto, M., Binaghi, G., Cesaro, A., Maloberti, A., et al. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07551-7 · Cited by 5
“In hypertension, the strategy of dual RAAS blockade (with an ACE-I associated with an ARB or Aliskiren) was tested in ALTITUDE, VA NEPHRON-D, and ONTARGET trials [41–43].”
Heerspink, H. J. L., Rabelink, T. J., & de Zeeuw, D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00054-8 · Cited by 3
Dual RAAS blocker trial stopped prematurely
Cully, M. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.169 · Cited by 3
Dual RAAS blocker trial stopped prematurely
Cully, M. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.254 · Cited by 3
Diseases of Renal Microcirculation: Diabetic Nephropathy
Riphagen, I. J., Heerspink, H. J. L., Gans, R. O. B., & Gaillard, S. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_149-1 · Cited by 3
“The Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE) study showed that aliskiren, compared to placebo, in addition to treatment with an ACEi or ARB, did not confer renal or cardiovascular protection despite additional blood pressure and albuminuria lowering (Parving et al. 2012).”
BackgroundPathophysiology of Hypertension in Chronic Kidney Disease and Dialysis
Griffin, K. A., Polichnowski, A. J., & BIDANI, A. K. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6436-9_3 · Cited by 3
CHRONIC RENAL DISEASE: RISK FACTORS, EARLY DETECTION, PRINCIPLES OF ANTIHYPERTENSIVE THERAPY
Easyan, A. M. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-12-18-25 · Cited by 4
“Результаты исследования ALTITUDE [48] с применени-ем прямого ингибитора ренина – алискирена в комбина-ции с иАПФ или БРА также оказались негативными.”
Recent Updates on Diabetic Nephropathy
Kee, Y. K., & Han, S. H. (2017) · Journal of Korean Diabetes · doi:10.4093/jkd.2017.18.4.214 · Cited by 3
“하지 만 이후 시행한 임상 시험에서는 RAAS 차단제에 aliskiren 을 추가하였을 때 신장 예후에 대한 개선 없이 위약군에 비 해 고칼륨혈증 발생이 유의하게 증가하고, 저혈압의 빈도가 많았으며, 더구나 심혈관 질환 발생빈도가 통계적으로 의미 있지는 않지만 더 많이 발생되어 안전성을 고려하여 조기 종료되었다[34].”
Afectación renal en la diabetes mellitus
Barrio, F. M., Torres, C. C., & Esparragoza, J. K. P. (2019) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2019.05.031 · Cited by 5
Балыкова, Л. А., Leontyeva, I. V., Krasnopolskaya, A. V., Sadykova, D. I., Mashkina, L. S., Chegodaeva, I. Y., Хабибрахманова, З. Р., Сластникова, Е. С., Галимова, Л. Ф., & Ushakova, S. A. (2021) · Вопросы современной педиатрии · doi:10.15690/vsp.v20i4.2281 · Cited by 6
“На основании обзора исследований ONTARGET [61], ALTITUDE [62] и VA NEPHRON-D [63] Европейское агентство по лекарственным средствам рекомендовало избегать сочетания ИАПФ и БРА по причине риска развития побочных эффектов (гиперкалиемии, повышения уровня креатинина более 30% от исходного уровня, нарушения функции почек и…”
How to treat hypertension? Current management strategies
Gopar‐Nieto, R., Ezquerra-Osorio, A., Chávez-Gómez, N. L., Manzur‐Sandoval, D., & Raymundo-Martínez, G. I. (2022) · Archivos de cardiolog�a de M�xico (English ed Internet) · doi:10.24875/acme.m21000255 · Cited by 3
Nephrotic syndrome in adults: symptoms and management
(2021) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2021.1.43065 · Cited by 5
Thomas, M. C. (2014) · Springer eBooks · doi:10.1007/978-3-642-54637-2_10 · Cited by 3
Intracellular Renin Protects Cardiomyocytes from Ischemic Injury in Diabetic Heart
Nonaka, D. (2015) · Journal of Cardiovascular Diseases & Diagnosis · doi:10.4172/2329-9517.1000214 · Cited by 3
“Interestingly, recent clinical trials demonstrated that direct renin inhibitor (DRI) did not improve, but worsened prognosis of type-2 DM patients with cardiovascular disease when added to standard heart failure therapy [17,18].”
BackgroundSosner, P., Fiquet, B., Quéré, S., Francillon, A., & Herpin, D. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328360f716 · Cited by 3
“However, it should be pointed out that this study was carried out before the results of the Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (ALTITUDE) trial were communicated [15].”
ResultNew nonabsorbable potassium-exchange resins in hyperkalaemia
Roscioni, S. S., & Heerspink, H. J. L. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.252 · Cited by 3
La néphropathie chronique en présence de diabète
McFarlane, P. A., Gilbert, R. E., MacCallum, L., & Senior, P. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.026 · Cited by 6
The Role of Systemic Blood Pressure in the Progression of Chronic Kidney Disease
Griffin, K. A., Pothugunta, K. S., Polichnowski, A. J., & BIDANI, A. K. (2015) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-015-0450-9 · Cited by 3
Resistant Hypertension: A Comprehensive Overview
Jentzer, J. C. (2013) · Journal of Hypertension Open Access · doi:10.4172/2167-1095.1000111 · Cited by 3
“In selected patients with refractory HTN and persistently elevated PRA, the MRA could be replaced with an ARB or direct renin inhibitor, but a sympatholytic may be preferred given the modest BP lowering and increased adverse events seen with dual renin-angiotensin system blockade [53,89,90].”
BackgroundKistner, I., Zeymer, U., Dechend, R., Hagedorn, I., Riemer, T., Bramlage, P., Pittrow, D. B., Senges, J., & Schmieder, R. E. (2016) · Journal of Clinical Hypertension · doi:10.1111/jch.12828 · Cited by 3
“Moreover, there was an increase in the rate of hyperkalemia, hypotension, and renal dysfunction in the aliskiren group, which is in line with its mechanism of action.(12) The use of aliskiren in combination with either an ACE inhibitor or an ARB is therefore now contraindicated in patients with diabetes.”
ResultInfluentialWhat constitutes optimal neurohumoral antagonism in chronic heart failure?
Tajik, A. A., & Dickstein, K. (2016) · Heart · doi:10.1136/heartjnl-2015-308039 · Cited by 3
Chronic kidney disease: definition, classification, diagnostics, and treatment
Kobalava, Z. D., Вадимовна, В. С., & Алексеевна, Е. М. (2013) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2013-4-95-103 · Cited by 7
Dual RAAS Blockade with Aliskiren in Patients with Severely Impaired Chronic Kidney Disease
Rasche, F. M., Joel, C., Ebert, T., Frese, T., Barinka, F., Busch, V., Rasche, W., Lindner, T. H., Schneider, J. G., & Schiekofer, S. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-106440 · Cited by 3
“Hyperkalemia was defined as potassium in serum > 5 mmol/l in accordance to the ALTITUDE study [24] with optimal pre-analytic conditions: non-hemolytic samples were immediately transported to the department of laboratory medicine, clinical chemistry and molecular diagnostics and directly analysed after centrifugation.”
BackgroundMethodPetrović, M., Dragovic, T., Petrović, S., Obrenčević, K., Rančić, N., Djurasinovic, T., Petrović, D., Ignjatović, L., Rabrenović, V., Nenezić, N., et al. (2018) · Vojnosanitetski pregled · doi:10.2298/vsp180525113p · Cited by 4
Mohmoodnia, L., Koushki, S., Moruzzi, M., Papi, S., Khorramabadi, R. M., Farzan, B., Hadian, B., & Hasanvand, A. (2019) · Immunopathologia Persa · doi:10.15171/ipp.2019.10 · Cited by 3
“Another similar study which assessed renoprotective effect of aliskiren in patients with type 2 diabetes showed that urinary albumin/ creatinine decreased after treatment with aliskiren in comparison with placebo (14%) (19).”
ResultCardiovascular Disease and Chronic Kidney Disease
Parfrey, P. S., & Barrett, B. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00016-0 · Cited by 3
Chapter 7. Hypertension complicated by other diseases
(2014) · Hypertension Research · doi:10.1038/hr.2014.10 · Cited by 4
Chronic Kidney Disease in Diabetes
(2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.02.029 · Cited by 3
Rôle des récepteurs cannabinoïdes au cours des maladies rénales
François, H., Dürrbach, A., Beaudreuil, S., Charpentier, B., & Lecru, L. (2016) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2016.02.004 · Cited by 3
Sourij, H., Edlinger, R., Prischl, F. C., Auinger, M., Kaser, S., Horn, S., Paulweber, B., Kautzky‐Willer, A., Säemann, M. D., Prager, R., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-018-1425-x · Cited by 3
Kaur, K. K., Allahbadia, G., & Singh, M. (2020) · Obesity Research - Open Journal · doi:10.17140/oroj-7-141 · Cited by 3
Dual RAS blockade—controversy resolved
Ruggenenti, P. L., & Remuzzi, G. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.82-c2 · Cited by 3
Borg, R., & Persson, F. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.02 · Cited by 3
“Following this, a series of studies investigated different modes of combination treatment seeking to further reduce albuminuria and obtain improved renal and cardiovascular protection (7-9).”
BackgroundSelf-citationTreatment Effects with Multiple Outcomes
Mullahy, J. (2018) · National Bureau of Economic Research · doi:10.3386/w25307 · Cited by 4
Systolic blood pressure target less than 120 mmHg: the ‘Chariot Allegory’ in hypertension?
Volpe, M., & Gallo, G. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002458 · Cited by 3
Ahmed, R., de Souza, R. J., Li, V., & Anand, S. S. (2022) · medRxiv · doi:10.1101/2022.06.28.22275821 · Cited by 4
Rossing, P. R., & Flyvbjerg, A. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch44 · Cited by 3
Non-albuminuric chronic kidney disease in diabetes
Borg, R., & Persson, F. (2022) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1018_22 · Cited by 2
Self-citationSmall, A. M., & Wiviott, S. D. (2024) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.24.06600-6 · Cited by 3
The era of combination of nephroprotective agents in CKD is there
Jadoul, M. Y., & Rossing, P. R. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae260 · Cited by 2
“…the end of the road: all three major trials (one of them using a direct renin inhibitor, aliskiren) showed increased risk of AKI and hyperkalemia with the combination of two agents blocking the RAS system, without clear evidence of additional nephroprotection compared with a single agent [7 –9 ].”
Arriola‐Montenegro, J., Chapoñan-Lavalle, A., Nombera-Aznaran, N., Abdalla, M. S., Bizer, B., Mohan, A., Verdugo, I. A. M., Zardoost, P., Ordaya-Gonzales, K., Rizzo, A. V., et al. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm45429 · Cited by 2
“While aliskiren can lower blood pressure, its role in RH is limited to highly selected cases under close monitoring due to increased risks of hyperkalemia, hypotension, and renal impairment, particularly in patients with diabetes or CKD [ 95].”
Jiang, Y., Hu, J., Yi, X., Li, Q., & Yang, S. (2026) · Drugs · doi:10.1007/s40265-026-02302-4 · Cited by 2
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062757 · Cited by 3
Treatment algorithms for hypertension: a practical approach
Neutel, J. M. (2013) · Clinical Practice · doi:10.2217/cpr.13.12 · Cited by 3
Can Aliskiren be Considered as a New Novel Drug for Hypertension?
Bhatti, A. B., & Gazali, Z. A. (2015) · Cureus · doi:10.7759/cureus.375 · Cited by 2
Utilisation and Tolerability of Aliskiren in the Primary Care Setting in England
Coughtrie, A. L., Doe, C., Layton, D., & Shakir, S. (2016) · Journal of Clinical Hypertension · doi:10.1111/jch.12852 · Cited by 2
Neue Aspekte der medikamentösen Nephroprotektion
Beimler, J. (2022) · Die Innere Medizin · doi:10.1007/s00108-022-01297-w · Cited by 3
Shah, S., Coakley, C., Hough, A. R., & Parra, D. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013512788 · Cited by 2
“Our patient tolerated aliskiren addition, showing no changes in potassium or renal function that would be suggestive of harm as proposed by the ALTITUDE trial outcomes.(24) It is possible that our patient may have benefited from earlier testing of his PRA to guide therapy, given that many medications that were empiric…”
ResultSyed, H., Naha, S., Khangura, D., Gardner, M., Kurukulasuriya, L. R., & Sowers, J. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_39 · Cited by 2
Hypertension and Chronic Kidney Disease Including Dialysis
Dhaybi, O. A., & Bakris, G. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00035-9 · Cited by 2
Clegg, L. E., Chu, L., Någård, M. B., Boulton, D. W., & Penland, R. C. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13084 · Cited by 2
“1,10,11 The shift in extracellular K + alters the transmembrane potential on cardiac myocytes and neurons, elevating risk of life-threatening cardiac arrhythmias and death.”
BackgroundClinical Assessment and Management of Chronic Kidney Disease Across its Stages
Collins, A. K., Rosenberg, M. E., & Kimmel, P. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00005-6 · Cited by 4
COMBINATION ANTIHYPERTENSION THERAPY: THE “UNDERRESEARCHED” COMBINATIONS
Kotovskaya, Y. V., Рунихина, Н. К., & Сергеевна, О. В. (2017) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2017-5-132-139 · Cited by 2
Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease
Lo, R. H., & Glassock, R. J. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_25 · Cited by 2
Clinical Assessment and Management of Chronic Kidney Disease Across Its Stages
Collins, A. K., Rosenberg, M. E., & Kimmel, P. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00005-x · Cited by 3
Rico-Fontalvo, J. E., Montejo-Hernández, J. D., Jiménez, L. C. V., Yánez, T. R., Daza-Arnedo, R., Cardona-Blanco, M., Lozano, J. L., & Rivero, M. P. (2023) · Anales de la Facultad de Ciencias Médicas (Asunción) · doi:10.18004/anales/2023.056.01.46 · Cited by 4
Maddury, S. R., Pande, A., Haque, K. M. H. S. S., Echtay, A. S., Go, L. O., Gulzar, T., Kadwa, M., & Hristoskova, S. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0005-8 · Cited by 2
“9 months [31].”
Treatment of albuminuria due to diabetic nephropathy: recent trial results
Horwitz, E. J., & Schelling, J. R. (2014) · Clinical Investigation · doi:10.4155/cli.14.19 · Cited by 3
Zeymer, U., Dechend, R., Riemer, T., Deeg, E., Senges, J., Pittrow, D. B., Schmieder, R. E., & the 3A Registry Investigators (2015) · Journal of Clinical Hypertension · doi:10.1111/jch.12725 · Cited by 2
“However, the active-treatment group experienced an increase in renal complications, hyperkalemia, and hypotension over 18 to 24 months of follow-up.(16) There was also a slight increase in cardiovascular events (death or stroke) in the ALIS group; however, the US Food and Drug Administration (FDA) did not reach a defi…”
BackgroundSaiz-Satjes, M., & Martínez-Martín, F. J. (2016) · Future Cardiology · doi:10.2217/fca-2016-0027 · Cited by 3
Albuminurie beim Diabetiker: praktisches Management
Kistler, A. D. (2013) · Praxis · doi:10.1024/1661-8157/a001429 · Cited by 2
“in Kombination mit einem ARB getestet und führte zu einer leicht stärkeren Reduktion der Proteinurie [30], zeigte in der ALTITUDE-Studie jedoch einen Trend in Richtung eines erhöhten Risikos für die meisten Endpunkte sowie ein deutlich erhöhtes Hyperkaliämierisiko [31].”
BackgroundShould all patients with significant proteinuria take a renin-angiotensin inhibitor?
Thomas, G., & Nally, J. V. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82a.15038 · Cited by 2
Kardiovaskuläre Pharmakotherapie: Risiken und Nebenwirkungen
Voigt, N., Heijman, J., & Dobrev, D. (2014) · Herz · doi:10.1007/s00059-014-4066-5 · Cited by 4
Hypertension in Patients with Chronic Kidney Disease
Varma, P. V., Chakravarthi, M. R., & Jyothsna, G. (2016) · Hypertension Journal · doi:10.5005/jp-journals-10043-0026 · Cited by 2
Capítulo 8 - Hipertensão e Condições Clínicas Associadas
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160158 · Cited by 4
Proteinurie im Kindesalter: Diagnostisches und therapeutisches Vorgehen
Liebau, M. C., & Weber, L. T. (2017) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-017-0284-2 · Cited by 2
Engeli, S., May, M., Nussberger, J., Danser, A. H. J., Dole, W. P., PRESCOTT, M. F., Dahlke, M., Stitah, S., Pal, P., Boschmann, M., et al. (2017) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2017.06.002 · Cited by 2
Questionable Conclusions Regarding Blood Pressure End Points
Rodgers, A., Atkins, E., & Salam, A. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0340 · Cited by 2
Use of azilsartan medoxomil in the primary-care setting in Germany: A real-world evidence study
EHLKEN, B., Shlaen, M., de Torres, M. D. P. L. F., Hisada, M., & Bennett, D. (2019) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp203359 · Cited by 3
“Dual RAAS blockade therapies combining a direct renin inhibitor aliskiren with an angiotensin-converting enzyme (ACE) inhibitor or an ARB have been associated with increased risk of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) [5, 6].”
BackgroundMatoses-Jaén, M. S., García-Claudio, N., Álvarez, J., & Argente-Navarro, P. (2020) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2019.11.010 · Cited by 3
Antihypertensive Efficacy of LCZ696 (Sacubitril/Valsartan) in Hypertension
Tocci, G. (2020) · Cardiology · doi:10.1159/000508345 · Cited by 2
Bakker, E., Mol, P. G. M., Nabais, J. M. V., Vetter, T., Kretzler, M., Nolan, J. J., Mayer, G. J., Sundgren, A. K., Heerspink, H. J. L., Schiel, A. E., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.662642 · Cited by 2
“After the introduction of ACEi and ARBs, many new and combination therapies have been studied in large clinical trials including further RAS-blockade, as well as targeting other biological mechanisms, but these did not result in further renal protection in patients with type 2 diabetes mellitus, and sometimes even res…”
BackgroundSindahl, P., Ofori‐Asenso, R., Hallgreen, C. E., Kemp, K., Gardarsdóttir, H., & Bruin, M. L. D. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15080 · Cited by 2
HIPERTENSÃO E DIABETES: CONCEITOS ATUAIS NA TERAPÊUTICA
Faculdade de Medicina de São José do Rio Preto (FAMERP), S., Cosenso‐Martin, L. N., Yugar‐Toledo, J. C., Faculdade de Medicina de São José do Rio Preto (FAMERP), S., Vilela-Martin, J. F., & Faculdade de Medicina de São José do Rio Preto (FAMERP), S. (2021) · Revista Brasileira de Hipertensão · doi:10.47870/1519-7522/20212803213-18 · Cited by 6
Polypharmacology in Clinical Applications: Renal Polypharmacology
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_9 · Cited by 2
MRA Inhibition in CKD: More Than Salt and Water
Gant, C. M., Laverman, G. D., & Navis, G. J. (2014) · Springer eBooks · doi:10.1007/978-3-319-09162-4_5 · Cited by 3
Metadata
- Authors
- Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., Richard, A., Xiang, Z., Brunel, P., & Pfeffer, M. A.
- Affiliations
- University of Copenhagen (DK)
- Brigham and Women's Hospital (US)
- The University of Texas at San Antonio Health Science Center (US)
- Imperial College London (GB)
- Steno Diabetes Centers (DK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-12-06
- Volume
- 367
- Issue
- 23
- Pages
- 2204-2213
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138862624
- Cited by
- 1,319
- References
- 40
- Citations by year
- 2026: 30 · 2025: 41 · 2024: 52 · 2023: 68 · 2022: 61 · 2021: 75 · 2020: 73 · 2019: 96 · 2018: 93 · 2017: 124 · 2016: 117 · 2015: 151 · 2014: 166 · 2013: 159 · 2012: 11
- FWCI
- 100.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- aliskiren, type 2 diabetes, chronic kidney disease, renin-angiotensin system blockade, ACE inhibitors, angiotensin receptor blockers, cardiovascular events, end-stage renal disease, hyperkalemia, hypotension, albumin-creatinine ratio, blood pressure reduction, cardiorenal outcomes
- MeSH terms
- Renin Inhibitors, Aged, Amides, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Fumarates, Humans, Hyperkalemia, Hypokalemia, Kidney Diseases, Male, Middle Aged, Patient Dropouts, Treatment Failure, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.